Where Does Wall Street Think PTC Therapeutics, Inc. (PTCT) Stock Will Go?

Analysts who follow PTC Therapeutics, Inc. (PTCT) on average expect it to decrease -4.22% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns PTC Therapeutics, Inc. an Analyst Ranking of 15, which means it ranks higher than 15 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating PTCT a Buy today. Find out what this means to you and get the rest of the rankings on PTCT!

See Full PTCT Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With PTC Therapeutics, Inc. Stock Today?

PTC Therapeutics, Inc. (PTCT) stock is trading at $30.54 as of 12:29 PM on Thursday, Mar 21, an increase of $1.03, or 3.49% from the previous closing price of $29.51. The stock has traded between $29.42 and $30.95 so far today. Volume today is light. So far 137,633 shares have traded compared to average volume of 930,991 shares. Click Here to get the full Stock Report for PTC Therapeutics, Inc. stock.